M3 (2413) Q3 2026 earnings summary

Executive summary

• Revenue for FY2025 Q1–Q3 rose 29% year-over-year to JPY 264,395 million, with operating profit up 24% and profit before tax up 23%.

• Growth was driven by both regular business acceleration, strong performance in Medical Platform, Patient Solution, and Overseas segments, and the conclusion of negative COVID-related sales impacts.

• A one-time gain of approximately JPY 4 billion from the sale of associate shares contributed to profit.

Financial highlights

• Revenue: JPY 264,395 million (+29% YoY); Operating profit: JPY 62,346 million (+24% YoY); Profit before tax: JPY 64,331 million (+23% YoY); Net profit: JPY 45,237 million (+27% YoY).

• Basic earnings per share increased to ¥61.42 from ¥47.93 year-over-year.

• Total assets grew to ¥644,353 million as of December 31, 2025, up from ¥581,741 million at March 31, 2025.

• Equity attributable to owners rose to ¥416,773 million, with a ratio of 64.7%.

• Total comprehensive income increased 44.2% year-over-year to ¥58,878 million.

Outlook and guidance

• FY2025 annual revenue is forecast at JPY 360,000 million, with operating profit targeted at JPY 70,000 million.

• Profit attributable to owners projected at ¥45,000 million, up 11.2%, with basic EPS of ¥66.27.

• The company aims for continued medium- to long-term business foundation expansion and growth.

• Dividend forecast for the fiscal year ending March 31, 2026, remains undetermined, pending review of capital needs and cash flow.